Page 122 - 《中国药房》2022年8期

milars/general/Biosimilars-of-bevacizumab. patients with stage Ⅳ nsNSCLC[EB/OL]. [2021-07-13].
[ 5 ] 国家食品药品监督管理总局.生物类似药研发与评价技 https：//clinicaltrials.gov/ct2/show/results/NCT04633564?
术指导原则：试行[EB/OL].[2021-07-13]. https：//www. id＝NCT02754882+OR+NCT04633564&draw＝2&rank＝
dcpc.com/xwzx/zcfg/gjsyjzj/201503/P0201503045414475- 1&load＝cart.
70315.pdf. [17] Boehringer Ingelheim. Phase Ⅲ trial BI 695502 plus che-
[ 6 ] 中国药品综合评价指南项目组.中国药品综合评价指南 motherapy vs. Avastin ® plus chemotherapy in patients
参考大纲：第二版[J].药品评价，2015，12（8）：6. with lung cancer[EB/OL].[2021-07-13]. https：//clinical-
[ 7 ] 郭瑞臣.抗肿瘤生物类似药的发展与临床应用[J].实用肿 trials.gov/ct2/show/NCT02272413?term＝NCT02272413&
瘤杂志，2020，35（4）：310-313. draw＝2&rank＝1.
[ 8 ] HODA S A. AJCC cancer staging manua，8th edition[J]. [18] THATCHER N，GOLDSCHMIDT J H，THOMAS M，et al.
Adv Anat Pathol，2017，24（2）：112. Efficacy and safety of the biosimilar ABP 215 compared
[ 9 ] EISENHAUER E A，THERASSE P，BOGAERTS J，et al. with bevacizumab in patients with advanced nonsqua-
New response evaluation criteria in solid tumours：revised mous non-small cell lung cancer（MAPLE）：a rando-
RECIST guideline：version 1.1[J]. Eur J Cancer，2009，45 mized，double-blind，phase Ⅲ study[J]. Clin Cancer Res，
（2）：228-247. 2019，25（7）：2088-2095.
[10] HIGGINS J P T，THOMAS J，CHANDLER J，et al. [19] YANG Y P，WU B，HUANG L N，et al. Biosimilar can-
Cochrane handbook for systematic reviews of inter- didate IBI305 plus paclitaxel/carboplatin for the treatment
ventions[EB/OL].[2021-07-13]. https：//training.cochrane. of non-squamous non-small cell lung cancer[J]. Transl
org/handbook. Lung Cancer Res，2019，8（6）：989-999.
[11] TRUKHIN D，PODDUBSKAYA E，ANDRIC Z，et al. [20] REINMUTH N，BRYL M，BONDARENKO I，et al.
Efficacy，safety and immunogenicity of MB02（bevacizu- PF-06439535（a bevacizumab biosimilar）compared with
mab biosimilar）versus reference bevacizumab in advanced reference bevacizumab（Avastin ），both plus paclitaxel
®
non-small cell lung cancer：a randomized，double-blind， and carboplatin，as first-line treatment for advanced
phase Ⅲ study（STELLA）[J]. BioDrugs，2021，35（4）： non-squamous non-small-cell lung cancer：a randomized，
429-444. double-blind study[J]. Bio Drugs，2019，33（5）：555-570.
[12] CHU T Q，LU J，BI M H，et al. Equivalent efficacy study [21] Biocad. A safety and efficacy study of BCD-021 with
of QL1101 and bevacizumab on untreated advanced non- paclitaxel and carboplatin compared to avastin with paclitaxel
squamous non-small cell lung cancer patients：a phase 3 and carboplatin in non-small cell lung cancer[EB/OL].[2021-
randomized，double-blind clinical trial[J]. Cancer Biol 07-13]. https：//clinicaltrials.gov/ct2/show/NCT01763645?
Med，2021，18（3）：816-824. term＝NCT01763645&draw＝2&rank＝1.
[13] Centus Biotherapeutics Limited. Evaluation of FKB238 [22] 毕明宏.贝伐珠单抗治疗非小细胞肺癌进展[J].临床肺科
and avastin in patients with advanced/recurrent non-squa- 杂志，2018，23（10）：1909-1914.
mous non-small cell lung cancer（AVANA）[EB/OL]. [2021- [23] SANDLER A，GRAY R，PERRY M C，et al. Paclitaxel-
07-13]. https：//clinicaltrials.gov/ct2/show/NCT02810457? carboplatin alone or with bevacizumab for non-small-cell
term＝NCT02810457&draw＝2&rank＝1. lung cancer[J]. N Engl J Med，2006，355（24）：2542-2550.
[14] SHI Y K，LEI K J，JIA Y M，et al. Bevacizumab biosimilar [24] PLANCHARD D，POPAT S，KERR K，et al. Correction
LY01008 compared with bevacizumab（Avastin）as first- to：“metastatic non-small cell lung cancer：ESMO clinical
line treatment for Chinese patients with unresectable，me- practice guidelines for diagnosis，treatment and follow-up”
tastatic，or recurrent non-squamous non-small-cell lung [J]. Ann Oncol，2019，30（5）：863-870.
cancer：a multicenter，randomized，double-blinded，phase [25] ETTINGER D S，AISNER D L，WOOD D E，et al. NCCN
Ⅲ trial[J]. Cancer Commun（Lond），2021，41（9）：889-903. guidelines insights：non-small cell lung cancer，version
[15] RECK M，LUFT A，BONDARENKO I，et al. A phase Ⅲ， 5.2018[J]. J Natl Compr Canc Netw，2018，16（7）：807-821.
randomized，double-blind，multicenter study to compare [26] CARGNIN S，SHIN J I，GENAZZANI A A，et al. Compa-
the efficacy，safety，pharmacokinetics，and immunogenicity rative efficacy and safety of trastuzumab biosimilars to the
between SB8 （proposed bevacizumab biosimilar） and reference drug：a systematic review and meta-analysis of
reference bevacizumab in patients with metastatic or recur- randomized clinical trials[J]. Cancer Chemother Pharmacol，
rent nonsquamous non-small cell lung cancer[J]. Lung 2020，86（5）：577-588.
Cancer，2020，146：12-18. （收稿日期：2021-09-17 修回日期：2022-02-23）
[16] Mylan Inc.. MYL-1402O compared with Avastin ，in （编辑：陈 宏）
®

·1008 · China Pharmacy 2022 Vol. 33 No. 8 中国药房 2022年第33卷第8期